Purpose: Previous studies demonstrate that threonine and tyrosine kinase (TTK) is overexpressed in triple-negative breast cancer (TNBC), but there are conflicting results regarding its effect on TNBC survival. The purpose of this study was to assess the prognostic significance of TTK expression in primary TNBC.
INTRODUCTION
Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide [1] . It consists of the luminal A, luminal B (HER2-negative), luminal B (HER2-positive), HER2-positive (non-luminal), and triple-negative (ductal) subtypes. Approximately 15% of invasive breast cancers are triplenegative breast cancers (TNBC) that lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions and usually exhibit a high pathological grade and more aggressive clinical behavior. Currently, chemotherapy is the only systemic treatment modality for TNBC patients.
The spindle assembly checkpoint (SAC) is a signaling cascade that prevents chromosome missegregation by arresting mitosis until all chromosomes are properly attached to the mitotic spindle [2] . As the core SAC kinase, TTK kinase is a dual-specificity kinase able to phosphorylate serine/threonine and tyrosine residues Research Paper [3] , and critical for the recruitment of SAC proteins to unattached kinetochores, mitotic checkpoint complex (MCC) formation, and mitotic arrest [4] . Thus, the inhibition of TTK activity causes cells to prematurely exit mitosis with unattached chromosomes, resulting in severe chromosome missegregation, aneuploidy, and eventually cell death [5] [6] [7] [8] . The increased expression of mitotic checkpoint genes contributes to chromosomal instability in cancer cells [9] [10] [11] [12] . Elevated TTK mRNA levels are found in several human cancers, including thyroid carcinoma, breast cancer, lung cancer, pancreatic cancer, prostate cancer, and melanoma, as well as glioblastoma and hepatocellular carcinoma-where it is associated with poor prognosis [9, 11, [13] [14] [15] [16] [17] [18] .
Previous studies show that TTK is overexpressed in breast cancer tissue and cells, particularly in the HER2-positive and TNBC subtypes [9, 10, 19, 20] . Whether it is also a prognostic factor in TNBC remains disputed. In the current study, we retrospectively analyzed TTK expression in 169 TNBC samples and investigated the correlation between TTK expression and TNBC prognosis.
RESULTS

Clinicopathological characteristics and survival data of the cohort
The present study enrolled 169 consecutive TNBC cases ( Table 1 ). The median age of patients at surgery was 51 years (range, 16-81 years). Most cases were immediate-to high-grade invasive breast ductal carcinoma (162/169, 95.5%), and 91.7% (155/169) of patients received a modified radical mastectomy. Of cases with available adjuvant treatment information, 99.3% (134/135) received chemotherapy (one ceased treatment because of an allergic reaction) and 34.3% (48/140) received radiation. Five cases lost follow-up. The median overall follow-up period was 1864 days (range, 1104-2373 days), and the five-year DFS and OS rates were 76.2% and 90.6%, respectively.
TTK expression and cutpoint determination
TTK expression was analyzed in 169 patients. Most samples (168/169, 99.4%) displayed cytoplasm and membrane staining, of which 10 cases (5.9%) had concomitant nuclear expression (Table 2, Figure 1) . Both "H-score. Cytoplasm & membrane" and "H-score. Whole cell" methods yielded a cutoff value of 55 with nearly identical p values (p < 0.001, Figure 2) ; however, the area under the curve (AUC) was slightly higher in the whole cell staining analysis, thus this scoring method was selected and the discriminating threshold set at 55.
Correlation between TTK and clinicopathological factors
The association between clinicopathological characteristics and TTK expression are summarized in Table 3 . No significant association was found between TTK status and age, histology subtype, grade, lymphovascular invasion (LVI), tumor size, number of positive lymph nodes, pathologic stage, Ki67 index, and p53 status; however, TTK overexpression was significantly higher in the basal-like TNBC subgroup.
Survival analysis
Clinical follow-up data were available for 164 out of 169 patients. Univariate survival analysis revealed that LVI, increased tumor size, positive lymph nodes, advanced stage, specific chemotherapy regimen (Anthracycline+Taxanes (AT)-based regimen), and lower TTK expression were associated with shorter DFS ( Table  4 ). All of these factors excepting increased tumor size, as well as radiation therapy, were also associated with a reduced OS ( Table 4 ). The Kaplan-Meier curves for DFS and OS against TTK expression are shown in Figure 3 . Conversely, age, surgery type, histology subtype, grade, p53 status, Ki67 index, and molecular subtype had no impact on survival in our study.
Cox regression multivariate analysis of DFS and OS revealed that TTK expression was an independent predictor for DFS (p < 0.001), but not for OS, whereas the number of positive lymph nodes was an independent predictor for both DFS (p < 0.001) and OS (p = 0.005) ( Table 5 ). Cox regression analysis results for other clinical variables are shown in Supplemental Table S1-S3.
Further subgroup analysis by log-rank testing showed that TTK expression associated with DFS in both basal-like (p = 0.001) and non-basal-like (p = 0.001) TNBC cases ( Figure 4) .
DISCUSSION
In the present study, it was found that TTK expression was associated with the TNBC molecular subtype and correlated with a better prognosis. Cox regression multivariate analysis confirmed TTK expression as an independent favorable prognostic indicator for TNBC. Consistent with our results, Maire et al [20] reported that low TTK mRNA expression in TNBC is significantly associated with a poorer overall survival, an increased risk of metastasis, and shorter DFS. However, AI-Ejeh et al [19] found that TTK protein levels were elevated specifically in highly aggressive tumors, leading to poor survival of less than 2 years. Both of the two studies had small sample sizes (39 and 69, respectively), and used different methods (RNA microarray analysis and IHC analysis) to determine expression. In addition, the latter study only used staining intensity to evaluate TTK protein expression, which might be far from a sufficient semi-quantitative assessment. Here, TTK protein expression was analyzed semi-quantitatively using the H-scoring system, which accounts for both staining intensity and the percentage of positive cells. A discriminating threshold for TTK expression was then determined with ROC curve analysis. This is the first study to evaluate the impact of TTK protein expression on the survival of a consecutive TNBC cohort with the largest sample size.
TTK has universally conserved functions at kinetochores to monitor the correct bipolar attachment and tension of all chromosomes to the mitotic spindle. Loss of TTK function causes chromosomal missegregation and induces cells apoptosis, while high level of TTK enable cells with higher aneuploidy to survive [9, 12, 16] . However, an auto-regulatory negative feedback loop between TTK and B-Raf WT /ERK signaling was found in melanoma cells [21] . Deregulation of B-Raf/ ERK signaling pathway is frequently observed and plays a central role in the carcinogenesis and maintenance of several cancers [22] . The negative feedback loop might exist in TNBC cells and low level of TTK activates the B-Raf/ERK signaling, which contributes to the invasiveness of cancer cells and poor survival of patients. Therefore, TTK plays a special and complicated role in breast cancer and should be regarded as an important regulator factor. The use of TTK expression as a positive prognostic indicator may help in personalized prognosis evaluation and treatment. Apart from the traditional prognostic indicators-ER, PR and HER2, assessment of the TTK expression provides additional prognostic information. For example, in patients with early breast cancer of hormone receptor positive and HER2 negative, a high level of TTK expression predicts a good survival and may spare adjuvant chemotherapy safely. However, a low level of TTK expression may hint the need of cytotoxic agents. The data also identified a low TTK-expression TNBC subset with significantly worse prognosis in both basallike and non-basal-like tumors. The molecular subgroup which was ER -/PR -/HER2 -/TTK low presented a quadratenegative phenotype and was defined as quadrate-negative breast cancer (QNBC) in the current study. In other words, the four-biomarker panel can identify some TNBC cases with dismal prognosis which might require more intense treatment than others.
Numerous studies suggest that TTK may be a promising drug target for anticancer therapy, and several small-molecule inhibitors targeting this kinase are currently under development [5] [6] [7] [8] [23] [24] [25] or have entered the clinic (BAY 1161909, NCT02138812; BAY 1217389, NCT02366949) [26] . However, the patient groups that would benefit from TTK-targeted therapy remain unclear. Moreover, because TTK is expressed in all proliferating human cells [27] , these inhibitors should be used cautiously to avoid severe adverse effects. TTK-567(SYRNEIAYL) epitope peptide was also used to elicit cytotoxic T lymphocytes to establish cancer vaccines in lung, esophageal and advanced biliary tract cancers [28, 29] .
This study has several limitations, primarily its retrospective nature and single-institution sample. The lack of a standard method to assess TTK expression is also a disadvantage. In addition, multicollinearity existed between lymph-vascular invasion, tumor size, number of positive lymph nodes, and pathological stage in the clinicopathological data, but these characteristics were considered separately in the Cox regression model. The Cox regression analysis showed TTK expression not an independent impact factor for OS. It might contribute to the small number of deaths and relative short follow-up period. For these reasons, a multi-institution prospective study with all molecular subtypes will be required to verify the prognostic role of TTK and to further assess the clinical significance of QNBC group.
In conclusion, while these findings should be confirmed with a larger patient population, our results suggest that TTK expression is a favorable independent prognostic biomarker for TNBC survival.
MATERIALS AND METHODS
Patients and tumor specimens
The study population included patients with unilateral TNBC who received curative surgery and consecutive enrolled patients ( Figure 5 ). The follow-up period lasted from the date of surgery until June 2016. The primary endpoint was Disease-free survival (DFS) and secondary endpoint was overall survival (OS). DFS and OS intervals were defined as the time from surgery to the date of breast cancer-related relapse or death, respectively. Relapsed disease and metastasis were verified by diagnostic imaging and pathology during follow-up. This study was approved by the Ethics Committee of PUMCH and informed consent was obtained from each patient.
Immunohistochemistry staining and analysis
All tissues were fixed in 10% neutral-buffered formalin immediately after surgical resection and embedded in paraffin. Serial sections (3-4 μm) were mounted on adhesion slides. Immunohistochemical staining was performed with a Ventana Benchmark XT autostainer using standard autostaining protocols (Ventana Medical Systems Inc., Tucson, AZ) and all slides were processed according to the manufacturer's protocols. The antibodies used for biomarker expression analysis and their optimized staining conditions are described in Table  6 . Positive and negative controls were performed using the manufacturer-recommended control tissue and isotype antibody respectively. IHC slides were evaluated by two experienced pathologists in a blinded manner. Positive staining was defined as cells with staining patterns specified in Table  6 . H-scoring was used to quantify TTK staining because no uniform standard exists [30] [31] [32] [33] [34] . For this, the overall staining intensity (0-3) was multiplied by the percentage of positive cells (0-100%), and all values were added to generate a final H-score ranging from 0 to 300. For ROC curve analysis, TTK staining was scored based on staining only in the cytoplasm and membrane ("H-score. Cytoplasm & membrane") or in the whole cell including cytoplasm, membrane and nucleus ("H-score. Whole cell"). The expression of other biomarkers was determined based on the cutoff value provided in Table 6 . For HER-2 specifically, staining intensities were rated as (0), (1+), (2+), and (3+) according to the HER2 test guide for breast cancer [35] . HER-2 (0) or (1+) slides were categorized as HER-2-negative, while HER-2 (3+) slides were classified as HER-2-positive. HER-2 (2+) cases were subjected to secondary analysis by fluorescent in situ hybridization (FISH) to confirm HER-2 status on a genetic basis, and those determined to be negative were enrolled in the present study. The five-biomarker immunopanel (ER, PR, HER2, CK5/6, EGFR) was also used to classify TNBC cases as basal-like (ER-/PR-/HER2-with EGFR+ and/ or CK5/6+) or non-basal-like (ER-/PR-/HER2-/EGFR-/ CK5/6-).
Statistical analysis
Statistical analysis was performed in SPSS 17.0 (SPSS, Chicago, IL, USA). Qualitative variables were compared with chi-square tests and univariate log-rank testing was used to assess the associations of DFS and OS with disease covariates to identify prognostic factors. Cox regression multivariate analysis was performed to determine the significance of prognostic factors. All p values were two sided and considered significant at α = 0.05. Receiver operating characteristic (ROC) curve analysis was used to assess the discriminatory power of prognostic factors to identify the optimal value of a continuous variable to differentiate between a probability of survival and death [36, 37] .
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